European Hematology Association Congress | Conference

Endotheliopathy: A Marker of Progression to Critical Illness in COVID-19

June 14th 2020

Endotheliopathy represents a marker of progression to critical illness in patients with COVID-19 infection and soluble thrombomodulin segregates with mortality.

Ropeginterferon Alfa-2b Helps Maintain Hematocrit Control for Low-Risk Polycythemia Vera

June 14th 2020

More patients with low-risk polycythemia vera treated with ropeginterferon alfa-2b were able to maintain hematocrit levels at or below 45% compared with those who received monthly phlebotomy alone.

Dr. Dimopoulos on the Safety of Zanubrutinib in Waldenström Macroglobulinemia

June 14th 2020

Meletios A. Dimopoulos, MD, discusses safety results from the randomized phase 3 ASPEN trial of zanubrutinib (Brukinsa) in patients with Waldenström macroglobulinemia.

Dr. Talati on Real-World Data With Venetoclax Combinations in AML

June 13th 2020

Chetasi Talati, MD, discusses the ongoing safety analysis of venetoclax (Venclexta)-based combinations in patients with newly diagnosed acute myeloid leukemia.

Eprenetapopt/Azacitidine Shows Encouraging Responses in High-Risk MDS/AML

June 13th 2020

The combination of eprenetapopt and azacitidine led to high objective response rates and complete response rates in patients with TP53-mutated myelodysplastic syndrome and acute myeloid leukemia.

Luspatercept-aamt Reduces RBC Transfusion Burden in Patients With Rare Blood Disorder

June 13th 2020

Data from the BELIEVE trial showed that luspatercept-aamt, a first-in-class erythroid maturation agent designed to regulate late-stage red blood cell maturation, reduced the need for red blood cell transfusions across every subgroup of patients with beta-thalassemia.

Early Data Show CC-93269 has Activity in Multiple Myeloma

June 13th 2020

Interim results from a phase 1 trial show CC-93269 has activity in highly refractory, heavily pretreated patients with multiple myeloma, with an acceptable safety profile.

Dr. Cluzeau on the Efficacy of APR-246/Azacitidine in TP53-Mutated MDS and AML

June 13th 2020

Thomas Cluzeau, MD, PhD, discusses the response rates of a phase 2 study with APR-246 and azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia.

Dr. DiNardo on the Results of the VIALE-A Trial in AML

June 13th 2020

Courtney DiNardo, MD, MSCE, discusses the results of the phase 3 VIALE-A trial in acute myeloid leukemia (AML).

Adding Subcutaneous Daratumumab to CyBorD Improves Outcomes for AL Amyloidosis

June 13th 2020

Subcutaneous daratumumab may be a promising treatment for newly diagnosed patients with light chain amyloidosis who are in urgent need of new treatment options.

Venetoclax/Azacitidine Showcases OS Benefit in Older Patients With AML

June 13th 2020

The combination of venetoclax (Venclexta) and azacitidine led to a 34% reduction in the risk of death versus azacitidine alone in treatment-naïve patients with acute myeloid leukemia who are ineligible for intensive therapy.

Narsoplimab Significantly Improves Outcomes in HSCT-TMA

June 12th 2020

Treatment with narsoplimab (OMS721) led to complete responses, improved laboratory markers, and encouraging 100-day survival rates in patients diagnosed with hematopoietic stem cell transplant-thrombotic microangiopathy.

Liso-Cel Induces High Response Rates in High-Risk Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

June 12th 2020

Treatment with the CAR T-cell product lisocabtagene maraleucel led to high response rates, with durable complete responses, in transplant-ineligible patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma who had poor prognostic features.

Dr. Hari on the Role of MRD in Multiple Myeloma

June 12th 2020

Parameswaran Hari, MD, MRCP, discusses the role of minimal residual disease in multiple myeloma.

Dr. Costa on Safety of CC-93269 in Relapsed/Refractory Myeloma

June 12th 2020

Luciano J. Costa, MD, PhD, discusses the safety results of CC-93269 in patients with relapsed/refractory multiple myeloma.

Serum Biomarkers Are Early Predictors for Haplo-SCT Outcomes

June 12th 2020

Higher levels of the serum biomarkers ST2 and REG3α were associated with increased incidence of graft-vs-host disease and increased risk for transplant-related mortality in patients who have undergone haploidentical stem-cell transplantation with post-transplant cyclophosphamide.

Pegcetacoplan Outperforms Current Standard of Care in Paroxysmal Nocturnal Hemoglobinuria

June 12th 2020

The novel C3 inhibitor pegcetacoplan led to a significant improvement in hemoglobin level and other clinical outcomes at week 16 versus the current standard of care, eculizumab in patients with paroxysmal nocturnal hemoglobinuria.

Ruxolitinib Improves Outcomes in aGVHD Across Subgroups

June 12th 2020

Ruxolitinib (Jakafi) induced a strong, durable response across several subgroups of patients with steroid-refractory acute graft-versus-host disease.

Ibrutinib/Venetoclax Triplet Demonstrates Frontline Activity in High-Risk CLL

June 12th 2020

The triplet regimen of ibrutinib, venetoclax, and obinutuzumab demonstrated encouraging response rates with an acceptable safety profile in treatment-naïve patients with high-risk chronic lymphocytic leukemia.

Imetelstat Provides Promising, Durable Transfusion Independence in Lower-Risk MDS

June 12th 2020

Imetelstat demonstrated meaningful and durable transfusion independence in patients with lower-risk myelodysplastic syndrome that are non-del(5q), dependent on red blood cell transfusion, and are relapsed/refractory to treatment with erythropoiesis-stimulating agents.